Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 9/20 | 0.48 |
| ▸ | GIPR | P48546 | 7/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | STAT3 | P40763 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289133 | 0.92 | GCGR (0.51) | GCGRGIPRSTAT3ALDH1A1MAPT | |
| SCHEMBL2647011 | 0.85 | CA1 (0.63) | CA1CA2ALDH1A1MAPTNPC1 | |
| SCHEMBL2654385 | 0.85 | CA1 (0.63) | CA1CA2ALDH1A1MAPTNPC1 | |
| SCHEMBL2655112 | 0.80 | GCGR (0.71) | GCGRGIPRSTAT3 | |
| SCHEMBL7560695 | 0.79 | CA1 (0.47) | CA1CA2STAT3ALDH1A1MAPT | |
| SCHEMBL2654897 | 0.78 | CA1 (0.54) | CA1CA2ALDH1A1MAPTNPC1 | |
| SCHEMBL2647473 | 0.77 | GCGR (0.69) | GCGRGIPRSTAT3 | |
| SCHEMBL2652815 | 0.77 | GCGR (0.57) | GCGRGIPRSTAT3 | |
| SCHEMBL2646743 | 0.77 | GCGR (0.73) | GCGRGIPRSTAT3 | |
| SCHEMBL6293030 | 0.77 | STAT3 (0.48) | GCGRGIPRSTAT3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885CA1 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.